Cohance Lifesciences’ shares plummeted 6% on September 18, 2025, due to a large block sale and speculation over a potential stake divestment by the company’s promoter, Jusmiral Holdings Ltd.

Jefferies initiates coverage on Cohance Lifesciences Ltd with a ‘Buy’ rating, setting a price target of ₹1,150 per share, citing the company’s potential in the evolving Indian Contract Research, Development, and Manufacturing Organization (CRDMO) …